Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
12h
Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
BioPharma Dive
12h
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
To lead Medicare, Medicaid
Tapped as education secretary
Iran's uranium stockpile
OK's landmine aid to UKR
Jets fire GM Joe Douglas
Atmospheric river alert
Travel guide innovator dies
Subway chokehold trial
Super Heavy Starship launch
Hush money case delayed
Microsoft pitches AI 'agents'
Tbilisi protest camp raided
UKR fires US-made missiles
Clemency decision delayed
US housing starts tumble
Attorney for accusers sued
Launches bid to lead DNC
22 trapped for 2 hours
Jeffries wins reelection
FEMA faces tough questions
Bulls legend dies at 81
Recommended content reset
Victims sue Colorado county
Lakers to honor Pat Riley
Crash ratings get update
Hacker accessed Gaetz file?
Updates nuclear doctrine
Rookie of the Year winners
WY abortion laws rejected
Feedback